Emerging insights into alternative end-joining: Mechanisms, genome instability and therapeutic opportunities in cancer (Review)

Genome instability is a central hallmark of cancer, driven by aberrant DNA damage responses that facilitate tumor evolution and resistance to therapy. Although canonical non-homologous end joining and homologous recombination are well-characterized pathways for repairing DNA double-strand breaks (DSBs), recent advances have revealed that cancer cells increasingly depend on alternative end-joining (alt-EJ) to survive persistent DNA damage that arises from intrinsic stresses or external therapies. Alt-EJ, characterized by its reliance on microhomologous sequences at DSB sites, promotes mutation accumulation and chromosomal rearrangements, thereby driving genomic instability and tumor progression. Despite its pivotal role in cancer biology, the molecular regulation, contextual determinants and dualistic role of alt-EJ in maintaining genome integrity compared with promoting instability remain incompletely understood. The present review integrated the latest mechanistic insights into alt-EJ, elucidated its regulatory networks and interactions with canonical DSB repair pathways and discussed its consequences for cancer genome integrity and evolution. Furthermore, it highlighted the emerging potential of alt-EJ as a therapeutic vulnerability for cancer, underscoring the urgent need to translate these discoveries into innovative treatment strategies aimed at overcoming therapy resistance and improving patient outcomes.

• Publication year

  2025

• Venue

  International Journal of Oncology

• Publication date

  2025-10-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/ijo.2025.5809PMID 41070620PMCID 12543316
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors.

  2025cited by this paper
• Mechanisms and regulation of DNA end resection in the maintenance of genome stability

  2025cited by this paper
• Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment

  2025cited by this paper
• Structural basis of error-prone DNA synthesis by DNA polymerase θ

  2025cited by this paper
• Research progress in DNA damage response (DDR)-targeting modulators: From hits to clinical candidates.

  2025cited by this paper
• LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers

  2025cited by this paper
• Multiple functions of PARP1 in the repair of DNA double strand breaks.

  2025cited by this paper
• Revisiting the TGFβ paradox: insights from HPV-driven cancer and the DNA damage response

  2025cited by this paper
• Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer

  2024cited by this paper
• Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

  2024cited by this paper
• Radiosensitization of Osteosarcoma Cells Using the PARP Inhibitor Olaparib Combined with X-rays or Carbon Ions

  2024cited by this paper
• A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging

  2024cited by this paper
• Advancing cancer therapy: new frontiers in targeting DNA damage response

  2024cited by this paper
• DNA polymerase α-primase facilitates PARP inhibitor-induced fork acceleration and protects BRCA1-deficient cells against ssDNA gaps

  2024cited by this paper
• Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors

  2024cited by this paper
• High-complexity of DNA double-strand breaks is key for alternative end-joining choice

  2024cited by this paper
• Telomere-related DNA damage response pathways in cancer therapy: prospective targets

  2024cited by this paper
• Mechanism of single-stranded DNA annealing by RAD52–RPA complex

  2024cited by this paper
• Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors

  2024cited by this paper
• Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies

  2023cited by this paper
• Novel insights into DNA damage repair defects in HPV-positive head and neck squamous cell carcinoma: from the molecular basis to therapeutic opportunities

  2023cited by this paper
• The APE2 nuclease is essential for DNA double-strand break repair by microhomology-mediated end joining.

  2023cited by this paper
• Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer

  2023cited by this paper
• RHINO directs MMEJ to repair DNA breaks in mitosis

  2023influential reference
• PARP molecular functions and applications of PARP inhibitors in cancer treatment

  2023cited by this paper
• Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.

  2023cited by this paper
• Molecular Pathways and Mechanisms of TGFβ in Cancer Therapy.

  2023cited by this paper
• Validation of anti-correlated TGFβ signaling and alternative end-joining DNA repair signatures that predict response to genotoxic cancer therapy.

  2022cited by this paper
• Polλ promotes microhomology-mediated end-joining

  2022cited by this paper
• POLQ seals post-replicative ssDNA gaps to maintain genome stability in BRCA-deficient cancer cells.

  2022cited by this paper
• POLθ processes ssDNA gaps and promotes replication fork progression in BRCA1-deficient cells.

  2022cited by this paper
• POLθ prevents MRE11-NBS1-CtIP-dependent fork breakage in the absence of BRCA2/RAD51 by filling lagging-strand gaps.

  2022cited by this paper
• Exploring the DNA damage response pathway for synthetic lethality

  2022cited by this paper
• Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

  2022cited by this paper
• The APE2 nuclease is essential for DNA double strand break repair by microhomology-mediated end-joining

  2022cited by this paper
• Characterization of sequence contexts that favor alternative end joining at Cas9-induced double-strand breaks

  2022cited by this paper
• Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)

  2022cited by this paper
• Therapeutic Targeting of DNA Damage Response in Cancer

  2022cited by this paper
• Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer

  2022cited by this paper
• APE2 Is a General Regulator of the ATR-Chk1 DNA Damage Response Pathway to Maintain Genome Integrity in Pancreatic Cancer Cells

  2021cited by this paper
• Mechanism, cellular functions and cancer roles of polymerase-theta-mediated DNA end joining

  2021cited by this paper
• Dual Inhibition of PARP and the Intra-S/G2 Cell Cycle Checkpoints Results in Highly Effective Radiosensitization of HPV-Positive HNSCC Cells

  2021cited by this paper
• Depletion of DNA Polymerase Theta Inhibits Tumor Growth and Promotes Genome Instability through the cGAS-STING-ISG Pathway in Esophageal Squamous Cell Carcinoma

  2021cited by this paper
• A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors

  2021cited by this paper
• Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

  2021cited by this paper
• Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer.

  2021cited by this paper
• Loss of TGFβ signaling increases alternative end-joining DNA repair that sensitizes to genotoxic therapies across cancer types

  2021influential reference
• Function and molecular mechanisms of APE2 in genome and epigenome integrity.

  2021cited by this paper
• Single‐strand annealing: Molecular mechanisms and potential applications in CRISPR‐Cas‐based precision genome editing

  2021cited by this paper
• In silico study of missense variants of FANCA, FANCC and FANCG genes reveals high risk deleterious alleles predisposing to Fanconi Anemia pathogenesis.

  2021cited by this paper
• Proton and photon radiosensitization effects of niraparib, a PARP‐1/‐2 inhibitor, on human head and neck cancer cells

  2020cited by this paper
• DNA polymerase theta (Polθ) - an error-prone polymerase necessary for genome stability.

  2020cited by this paper
• HPF1 completes the PARP active site for DNA damage-induced ADP-ribosylation

  2020cited by this paper
• Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints

  2020cited by this paper
• Targeting DNA repair pathways: mechanisms and potential applications in cancer therapy

  2020cited by this paper
• Charting a DNA Repair Roadmap for Immunoglobulin Class Switch Recombination.

  2020cited by this paper
• Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.

  2020cited by this paper
• DNA end resection and its role in DNA replication and DSB repair choice in mammalian cells

  2020influential reference
• Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.

  2020cited by this paper
• ATM antagonizes NHEJ proteins assembly and DNA-ends synapsis at single-ended DNA double strand breaks

  2020cited by this paper
• Exploiting the Microhomology-Mediated End-Joining Pathway in Cancer Therapy

  2020influential reference
• Endogenous DNA 3' Blocks Are Vulnerabilities for BRCA1 and BRCA2 Deficiency and Are Reversed by the APE2 Nuclease.

  2020cited by this paper
• Olaparib for Metastatic Castration-Resistant Prostate Cancer.

  2020cited by this paper
• Sensitization of chondrosarcoma cells with PARP inhibitor and high-LET radiation

  2019cited by this paper
• Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.

  2019influential reference
• Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.

  2019cited by this paper
• Misrepair in Context: TGFβ Regulation of DNA Repair

  2019cited by this paper
• Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

  2019cited by this paper
• Human papillomavirus 16 promotes microhomology-mediated end-joining

  2019cited by this paper
• Harnessing DNA Double-Strand Break Repair for Cancer Treatment

  2019cited by this paper
• Mechanistic basis for microhomology identification and genome scarring by polymerase theta

  2019cited by this paper
• Chromosome instability syndromes

  2018cited by this paper
• Main steps in DNA double-strand break repair: an introduction to homologous recombination and related processes

  2018cited by this paper
• Role of apurinic/apyrimidinic nucleases in the regulation of homologous recombination in myeloma: mechanisms and translational significance

  2018cited by this paper
• Subjugation of TGFβ Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End Joining

  2018influential reference
• PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53

  2018cited by this paper
• Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.

  2018cited by this paper
• The therapeutic significance of mutational signatures from DNA repair deficiency in cancer

  2018cited by this paper
• Homologous recombination and the repair of DNA double-strand breaks

  2018cited by this paper
• Mechanisms of DNA damage, repair, and mutagenesis

  2017cited by this paper
• Enhancement of BLM-DNA2-Mediated Long-Range DNA End Resection by CtIP.

  2017cited by this paper
• Rad52 competes with Ku70/Ku86 for binding to S-region DSB ends to modulate antibody class-switch DNA recombination

  2017cited by this paper
• Telomeres in cancer: tumour suppression and genome instability

  2017cited by this paper
• Complex DNA Damage Induced by High Linear Energy Transfer Alpha-Particles and Protons Triggers a Specific Cellular DNA Damage Response

  2017cited by this paper
• PAXX promotes KU accumulation at DNA breaks and is essential for end-joining in XLF-deficient mice

  2017cited by this paper
• Dual loss of human POLQ and LIG4 abolishes random integration

  2017cited by this paper
• Microhomology-mediated end joining induces hypermutagenesis at breakpoint junctions

  2017cited by this paper
• Non-homologous DNA end joining and alternative pathways to double-strand break repair

  2017influential reference
• Genomic landscape of DNA repair genes in cancer

  2016cited by this paper
• Redundant function of DNA ligase 1 and 3 in alternative end-joining during immunoglobulin class switch recombination

  2016cited by this paper
• Genomic Scars Generated by Polymerase Theta Reveal the Versatile Mechanism of Alternative End-Joining

  2016cited by this paper
• Essential Roles for Polymerase θ-Mediated End Joining in the Repair of Chromosome Breaks.

  2016cited by this paper
• Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib

  2016cited by this paper
• Regulation of Single-Strand Annealing and its Role in Genome Maintenance.

  2016cited by this paper
• Coordinated nuclease activities counteract Ku at single-ended DNA double-strand breaks

  2016cited by this paper
• DNA Polymerase θ: A Unique Multifunctional End-Joining Machine

  2016cited by this paper
• Co-inhibition of pol θ and HR genes efficiently synergize with cisplatin to suppress cisplatin-resistant lung cancer cells survival

  2016cited by this paper
• DNA polymerase θ (POLQ), double-strand break repair, and cancer.

  2016cited by this paper
• Repair Pathway Choices and Consequences at the Double-Strand Break.

  2016cited by this paper
• DNA Damage Response Factors from Diverse Pathways, Including DNA Crosslink Repair, Mediate Alternative End Joining

  2015cited by this paper

• No citing papers are available for this paper.